BioLargo Inc. (OTCQX:BLGO) reported its 2025 annual financial results, showing a 56% drop in consolidated revenue to $7.77 million from $17.78 million in 2024, driven primarily by a sharp decline in sales to its largest private‑label odor‑control customer.
The company posted a net loss of $15.19 million for the year, a widening from the $4.35 million loss reported in 2024. The increase was largely due to a $3.89 million credit‑loss expense related to a customer default that is now the subject of litigation.
Cash‑flow pressure intensified, with operating cash outflows of $8.30 million and year‑end cash of $3.88 million, leaving working capital of only $51,000. The auditor noted substantial doubt about BioLargo’s ability to continue as a going concern.
Despite the financial setbacks, BioLargo continued to invest in its cleantech platforms, allocating $2.59 million to research and development in 2025. The company highlighted ongoing work on its AEC PFAS water‑treatment system, Cellinity™ liquid sodium batteries, and Clyra Medical’s wound‑care products.
Management acknowledged the challenges, noting that the loss of sales to Pooph Inc. and the resulting license termination and litigation have disrupted the company’s consumer‑product momentum. The company remains heavily reliant on external equity financing, which dilutes existing shareholders.
The results underscore a significant shift in BioLargo’s revenue mix and financial health, raising concerns about the company’s short‑term liquidity and long‑term viability while highlighting its continued commitment to technology development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.